Precision BioSciences, Inc.
NASDAQ:DTIL
Overview | Financials
Company Name | Precision BioSciences, Inc. |
Symbol | DTIL |
Currency | USD |
Price | 3.81 |
Market Cap | 29,226,735 |
Dividend Yield | 0% |
52-week-range | 3.61 - 19.43 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael Amoroso |
Website | https://www.precisionbiosciences.com |
An error occurred while fetching data.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD